Polyomavirus-associated nephropathy: Update of clinical management in kidney transplant patients

Transplant Infectious Disease

Volumn 8, Issue 2, 2006, Pages 76-85

  Trofe, J ^a   Hirsch, H H ^b   Ramos, E ^c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

BK virus; Cidofovir; Fluoroquinolone antibiotics; Immunosuppression reduction; Intravenous immunoglobulin; Kidney transplantation; Leflunomide; Polyomavirus nephropathy

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CIDOFOVIR; CYCLOSPORIN; GATAFLOXACIN; IMMUNOGLOBULIN; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ALGORITHM; ANTIVIRAL ACTIVITY; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DOSE REDUCTION; GRAFT FAILURE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; POLYOMAVIRUS ASSOCIATED NEPHROPATHY; PRIORITY JOURNAL; REVIEW; SCREENING; UNSPECIFIED SIDE EFFECT; URINE CYTOLOGY; VIREMIA;

BK VIRUS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; POLYOMAVIRUS INFECTIONS;

EID: 33744782602     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2006.00166.x     Document Type: Review

References (46)

1. Ramos E Drachenberg CB Portocarrero M, et al. BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. In: Cecka J Terasaki P, eds. Clinical Transplants 2002. Los Angeles: UCLA Immunogenetics Center, 2002: 143 153.
2. Nickeleit V Hirsch HH Binet IF, et al. Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease. J Am Soc Nephrol 1999: 10: 1080 1089.
3. Randhawa PS Finkelstein S Scantlebury V, et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 1999: 67: 103 109.
4. Hirsch HH Knowles W Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002: 347: 488 496.
5. Randhawa PS Vats A Zygmunt D, et al. Quantitation of viral DNA in renal allograft tissue from patients with BK virus nephropathy. Transplantation 2002: 74: 485 488.
6. Ramos E Drachenberg CB Papadimitriou JC, et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002: 13: 2145 2151.
7. Trofe J Cavallo T First MR, et al. Polyomavirus in kidney and kidney-pancreas transplantation: a defined protocol for immunosuppression reduction and histologic monitoring. Transplant Proc 2002: 34: 1788 1789.
8. Hirsch HH Brennan DC Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005: 79: 1277 1286.
9. Hirsch HH Steiger J. Polyomavirus BK. Lancet Infect Dis 2003: 3: 611 623.
10. Limaye AP Smith KD Cook L, et al. Polyomavirus nephropathy in native kidneys of non-renal transplant recipients. Am J Transplant 2005: 5: 614 620.
11. Barri YM Ahmad I Ketel BL, et al. Polyoma viral infection in renal transplantation: the role of immunosuppressive therapy. Clin Transplant 2001: 15: 240 246.
12. Buehrig CK Lager DJ Stegall MD, et al. Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney Int 2003: 64: 665 673.
13. Brennan DC Agha I Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005: 5: 582 594.
14. Ginevri F De Santis R Comoli P, et al. Polyomavirus BK infection in pediatric kidney-allograft recipients: a single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation 2003: 75: 1266 1270.
15. Vasudev B Hariharan S Hussain S Zhu Y Bresnahan B Cohen E. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int 2005: 68: 1834 1839.
16. Williams JW Javaid B Kadambi PV, et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 2005: 352: 1157 1158.
17. Andrei G Snoeck R Vandeputte M De Clercq E. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 1997: 41: 587 593.
18. Kadambi PV Josephson MA Williams J, et al. Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant 2003: 3: 186 191.
19. Vats A Shapiro R Randhawa PS, et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 2003: 75: 105 112.
20. Kuypers DR Vandooren AK Lerut E, et al. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 2005: 5: 1997 2004.
21. Lipshutz GS Flechner SM Govani MV Vincenti F. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant 2004: 4: 2132 2134.
22. Lipshutz GS Mahanty H Feng S, et al. BKV in simultaneous pancreas-kidney transplant recipients: a leading cause of renal graft loss in first 2 years post-transplant. Am J Transplant 2005: 5: 366 373.
23. Tong CY Hilton R MacMahon EM, et al. Monitoring the progress of BK virus associated nephropathy in renal transplant recipients. Nephrol Dial Transplant 2004: 19: 2598 2605.
24. Lim WH Mathew TH Cooper JE Bowden S Russ GR. Use of cidofovir in polyomavirus BK viral nephropathy in two renal allograft recipients. Nephrology 2003: 8: 318 323.
25. Keller LS Peh CA Nolan J Bannister KM Clarkson AR Faull RJ. BK transplant nephropathy successfully treated with cidofovir. Nephrol Dial Transplant 2003: 18: 1013 1014.
26. Bjorang O Tveitan H Midtvedt K Broch LU Scott H Andresen PA. Treatment of polyomavirus infection with cidofovir in a renal-transplant recipient. Nephrol Dial Transplant 2002: 17: 2023 2025.
27. Farasati NA Shapiro R Vats A Randhawa P. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 2005: 79: 116 118.
28. Snoeck R Andrei G Lilja H, et al. Activity of malononitrilamide compounds against murine and simian polyomavirus. In: 5th International Conference on New Trends in Clinical and Experimental Immunosuppression [Abstract], Geneva, Switzerland, 2002.
29. Puliyanda D Amet N Archana D, et al. IVIG contains antibodies reactive with polyomavirus BK and may represent a therapeutic option for BK nephropathy. Am J Transplant 2003: 3 Suppl. 5: 393 [Abstract 941].
30. Smith JM McDonald RA Finn LS Healey PJ Davis CL Limaye AP. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant 2004: 4: 2109 2117.
31. Sener A House AA Jevnikar AM, et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation 2006: 81: 117 120.
32. Cibrik DM O Toole JF Norman SP, et al. IVIG for the treatment of BK nephropathy. Am J Transplant 2003: 3 Suppl. 5: 370 [Abstract 850].
33. Trofe J Radhakrishnan S Shollar D, et al. Intravenous immunoglobulin preparations do not provide substantial neutralizing BKV antibody for treatment of polyomavirus nephropathy. J Neurovirol 2005: 11 Suppl. 2: 75.
34. Ferrazzi E Peracchi M Biasolo MA Faggionato O Stefanelli S Palu G. Antiviral activity of gyrase inhibitors norfloxacin, coumermycin A1 and nalidixic acid. Biochem Pharmacol 1988: 37: 1885 1886.
35. Portolani M Pietrosemoli P Cermelli C, et al. Suppression of BK virus replication and cytopathic effect by inhibitors of prokaryotic DNA gyrase. Antiviral Res 1988: 9: 205 218.
36. Chandraker A Ali S Drachenberg CB, et al. Use of fluoroquinolones to treat BK infection in renal transplant recipients. Am J Transplant 2004: 4 Suppl. 8: 587 [Abstract 1564].
37. Leung AY Chan MT Yuen KY, et al. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogenic hematopoietic stem cell transplantation. Clin Infect Dis 2005: 40: 528 537.
38. Ramos E Vincenti F Lu WX, et al. Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation 2004: 77: 131 133.
39. Drachenberg C Papadimitriou JC Hirsch H, et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant 2004: 4: 2082 2092.
40. Trofe J Gordon J Roy-Chaudhury P, et al. Correlation of BK viral load monitoring and host immune response in post-transplant polyomavirus nephropathy (PVAN). Am J Transplant 2003: 3 Suppl. 5: 370 [Abstract 852].
41. Ramos E Wali R Klassen DK, et al. Early diagnosis of polyomavirus nephropathy (PVAN) improves allograft outcome. Am J Transplant 2005: 5 Suppl. 11: 559.
42. Ramos E Drachenberg CB Portocarrero M, et al. Effects of type of immunosuppression reduction in patients with BK allograft nephropathy. Am J Transplant 2003: 561: [Abstract #1596].
43. Wali RK Drachenberg C Hirsch HH, et al. BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation 2004: 78: 1069 1073.
44. Womer KL Meier-Kriesche HU Patton PR, et al. Polyoma viral infection in renal transplantation: the role of immunosuppressive therapy. Am J Transplant 2006: 6: 209 213.
45. Hirsch HH Ramos E. Retransplantation after polyomavirus-associated nephropathy: just do it? Am J Transplant 2006: 6: 7 9.
46. Drachenberg CB Papadimitriou JC Ramos E. Histologic versus molecular diagnosis of BK polyomavirus allograft nephropathy: a shifting paradigm? Clin J Am Soc Nephrol 2006: 1: 374 379.